130 results about "Alpha helix" patented technology

Polymerases from the Pol I family which are able to efficiently use ddNTPs have demonstrated a much improved performance when used to sequence DNA. A number of mutations have been made to the gene coding for the Pol II family DNA polymerase from the archaeon Pyrococcus furiosus with the aim of improving ddNTP utilisation. "Rational" alterations to amino acids likely to be near the dNTP binding site (based on sequence homologies and structural information) did not yield the desired level of selectivity for ddNTPs. However, alteration at four positions (Q472, A486, L490 and Y497) gave rise to variants which incorporated ddNTPs better than the wild type, allowing sequencing reactions to be carried out at lowered ddNTP:dNTP ratios. Wild type Pfu-Pol required a ddNTP:dNTP ratio of 30:1; values of 5:1 (Q472H), 1:3 (L490Y), 1:5 (A486Y) and 5:1 (Y497A) were found with the four mutants; A486Y representing a 150-fold improvement over the wild type. A486, L490 and Y407 are on an alpha-helix that lines the dNTP binding groove, but the side chains of the three amino acids point away from this groove; Q472 is in a loop that connects this alpha-helix to a second long helix. None of the four amino acids can contact the dNTP directly. Therefore, the increased selectivity for ddNTPs is likely to arise from two factors: 1) Small overall changes in conformation that subtly alter the nucleotide triphosphate binding site such that ddNTPs become favoured; 2) interference with a conformational change that may be critical both for the polymerisation step and discrimination between different nucleotide triphosphates.

The present invention provides a novel material for activating epidermal cell multiplication on which not only effective adhesion and multiplication of human and mammalian epidermal cells is accomplished also intercellular adhesion is promoted to form a plain cellular layer. The present invention provides a material for activating epidermal cell multiplication which contains silk fibroin of alpha-type or alpha-helix X-ray diffraction pattern as a principal constituent. The present material fulfills the principal requirements for activating epidermal cells of greatly improved cellular adhesion rate, multiplication, intercellular adhesion and growth of cell layers.

A peptide with an amino acid composition such that the peptide is amphipathic, cationic and forms a stable alpha-helix and has the following structure comprising at least 12 amino acidsA=an amino acid selected from the basic amino acids Lys,Arg or HisB=an amino acid selected from the aromatic amino acids Phe, Trp or TyrC=an amino acid selected from the group comprising the hydrophobic amino acids Leu, Ile, Val or Ala, andsaid peptide has either the orientation according to the formula or the retro orientation thereof, wherein at least 0-m of the repetitive sequence motifs (A2-B2-C1-A3) have the retro orientation and the remaining repetitive motifs (A2-B2-C1-A3) have the orientation as presented in the formula and wherein,R1-R2- and R3 are a number of amino acids, and whereinm=1-10, preferably 2-8, more preferably 2-5 andn=1-3, a pharmaceutical composition comprising such a peptide application thereof in treatment or diagnosis related to i.a. parasite infection topical and systemic tumors and septic shock.

Functionalized pyridazine derivatives having a low molecular weight and pharmaceutical compositions thereof are useful as alpha-helix mimetics and for treating conditions and/or disorders mediated by alpha-helix-binding receptors and proteins.

A chimeric polyvalent recombinant protein for use as a vaccine and diagnostic for Lyme disease is provided. The chimeric protein comprises epitopes of the loop 5 region and/or the alpha helix 5 region of outer surface protein C (OspC) types. The OspC types may be associated with mammalian Borrelia infections.

The invention provides structurally-constrained peptides by hydrocarbon stapling of a BCL9 HD2 helix for use as a therapeutic agent. The invention further provides methods and kits for use of the structurally-constrained peptide of the instant invention. The invention is based, at least in part, on the results provided herein demonstrating that hydrocarbon stapled helical peptides display excellent proteolytic, acid, and thermal stability, restore the native helical structure of the peptide, possess superior pharmacokinetic properties compared to the corresponding unmodified peptides, and are highly effective in binding to β-catenin in vitro, in cellulo, and in vivo, disrupting the BCL-9/β-catenin interaction, and thereby interfering with deregulated Wnt/β-catenin signaling for therapeutic benefit in a variety of human diseases including human cancer.

In one aspect, the invention relates to peptides comprising the Bcr-Abl coiled-coil oligomerization domain and an alpha helix stabilizing moiety, mutant forms thereof, truncated forms thereof, derivatives thereof, and related peptides, which are useful as inhibitors of the Bcr-Abl chimeric protein; pharmaceutical compositions comprising the compounds; and methods of treating hyperproliferative disorders associated with Bcr-Abl using the compounds and compositions. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.

The invention discloses a polypeptide and nanometer particles thereof for carrying antigen peptides, preparation methods and applications thereof, and belongs to the field of biological science and drug carriers. The polypeptide is formed by series connection of an alpha-helix polypeptide, a connecting sequence and an antigen peptide in a covalent bond manner, wherein the amino acid sequence of the alpha-helix polypeptide is FAEKFKEAVKDYFAKFWD, the amino acid sequence of the connecting sequence is GSG, and the connecting sequence of the antigen peptide is KVPRNQDWL. The polypeptide and the nanometer particles prepared from the polypeptides are capable of effectively improving the tumor antigen peptide uptake efficiency of the dendritic cells and promoting the prevention and treatment effect of tumors after the DC (dendritic cell) takes in the antigen peptides.

The invention discloses double-target polypeptide of a tumor-associated macrophage, a nano particle, preparation and an application and relates to the technical field of bioscience and drug carriers.The double-target polypeptide is prepared by series connection of alpha helix polypeptide, a catenation sequence and M2 macrophage target peptide in a covalent bond form. The nano particle prepared bythe double-target polypeptide can perform efficient targeted transportation of drugs to the tumor-associated macrophage, so that the tumor-associated macrophage is specifically eliminated and tumor growth is inhibited; a preparation technology of the nano particle targeting to the tumor-associated macrophage is simple; large-scale production is facilitated; most raw materials for preparing the nano particle are used clinically or used in clinical experiments; and a detection result shows that no toxic or side effects are caused on physiologic and biochemical indexes of a mouse.

The invention provides α-mimetic structures and a chemical library relating thereto. Additionally, the invention provides methods wherein α-mimetic compounds are used to treat fibrotic disorders.

The invention relates to an amphiphilic alpha helix self-assembling peptide derived from SEQ ID NO:1 and an application of the amphiphilic alpha helix self-assembling peptide in protein production and purification. When the amphiphilic alpha helix self-assembling peptide and target protein are subjected to fusion expression, the amphiphilic alpha helix self-assembling peptide can induce the fusion protein to form active aggregate in cell, by comparing with polypeptide in SEQ ID NO: 1, the spatial distribution of the formed active aggregate in the cell is changed, a host cell growth state is improved, and fusion protein output is increased.

The present invention provides a protein scaffold, such as an avian pancreatic polypeptide, that can be modified by substitution of two or more amino acid residues that are exposed on the alpha helix domain of the polypeptide when the polypeptide is in a tertiary form.

The invention relates to an efficient alpha-helix antibacterial peptide GV and a preparation method and application thereof. The antibacterial peptide GV is an antibacterial peptide with high cell selectivity and achieves an optimal point of junction of the antibacterial activity and cell toxicity of the antibacterial peptide. A sequence of the antibacterial peptide GV is represented by a sequence table SEQ ID No. 1. The preparation method comprises the following steps: (1) carrying out designing in accordance with alpha-helix peptide GRX2RX3RX2RG serves as a template, so as to obtain a brand-new antibacterial peptide GV, wherein X= V; (2) synthesizing a polypeptide crude product through a polypeptide synthesizer by a solid-phase chemical synthesis method; purifying the synthesized polypeptide by using out-phase high-performance liquid chromatography, and carrying out identification on the synthesized polypeptide by using electrospray mass spectrography, thereby preparing the polypeptide. The antibacterial peptide GV provided by the invention has relatively high bacteriostatic activity and relatively low hemolytic activity and is the highest in therapeutic index, thereby having great development potential.

The invention discloses a polypeptide, a lipoprotein-like nano particle (LNP) and application thereof. The LNP contains at least one phospholipid and at least one polypeptide. A polypeptide series helix-ring-helix structure polypeptide contains at least two amphiphilic alpha helixes, and the two amphiphilic alpha helixes are connected through at least one connecting peptide containing a cyclic structure. The helix part of the polypeptide is imbedded into a lipoprotein-like nano particle surface layer, stable formation of lipid nano particles with uniform size and relatively small particle diameters can be promoted, meanwhile cyclic sequences stretch out of the surfaces of the lipoprotein-like nano particles, and functional sequence insertion is further facilitated, so that multi-functionalization of the LNP is realized. Moreover, the application of the LNP can be further expanded by using an LNP packaged lyophobically functional substance, and for example, the LNP can be used as a drug delivery system; the drug delivery system has the characteristics of being low in toxicity and high in stability, facilitating functionalization and the like, and a simple, convenient and effective means is provided for target killing of cancer cells and cell and tissue imaging.

Methods and compositions are provided for binding a target molecule comprising expressing a recombinant binding protein, such as an anticalin, an OB-domain protein, or an alpha-helix coiled-coil forming polypeptide in a plant. Methods for producing such a recombinant binding protein that binds to a target molecule are also provided. Further provided are plant lipocalin, OB-domain, and alpha-helix coiled-coil forming polypeptide coding sequences and recombinant polypeptides derived therefrom.

The invention provides an alpha helix cationic polypeptide as well as a preparation method and application of the alpha helix cationic polypeptide. The alpha helix cationic polypeptide takes a photosensitizer porphyrin as a core and alpha helix polypeptides as four arms, and a nucleotide drug prepared from the polymer can be applied to a nucleotide drug delivery system. The polymer provided by theinvention has good biocompatibility, low cytotoxicity and light activation ability. The polymer provided by the invention is self-assembled in a water solution to form nanoparticles which has good stability, biocompatibility and low cytotoxicity; the preparation method is simple and high in repeatability, and the polymer serving as a carrier is not only capable of protecting nucleic acid such asDNA from being degraded, but also capable of being combined with the scale effect of the nanoparticles so as to be used for treating diseases; and in addition, the transfection promoting effect for different cancer cells can be achieved by virtue of the light activation ability.